Medpace Investors Face Early-June Deadline to Seek Lead Role in Securities Case

The drive follows Medpace's February report of a weak book-to-bill ratio that sent the stock lower.

Overview

Robbins Geller said investors who bought between April 22, 2025 and February 9, 2026 can seek to be lead plaintiff by June 8, 2026 in a case filed in the Southern District of Ohio.
Glancy Prongay issued a separate notice urging shareholders with losses to contact the firm and pointed to the same June 8 deadline.
The litigation traces to Medpace’s February 9, 2026 results, which showed a 1.04 book-to-bill ratio versus 1.15 guidance after an uptick in backlog cancellations.
Following that disclosure, the stock closed down 15.9% to $446.05 on February 10, 2026, which the notices cite as investor harm.
In securities class actions, the court first appoints a lead plaintiff who directs the case, and law‑firm notices recruiting candidates are attorney advertising.